Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes
Launched by THOMAS JEFFERSON UNIVERSITY · Oct 8, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of when to perform a surgery called cranioplasty, which involves placing a bone flap back over the skull after a procedure called decompressive hemicraniectomy (DHC). DHC is done to relieve pressure on the brain after serious injuries like trauma or stroke. The trial aims to find out if doing cranioplasty early (within 8 weeks after DHC) leads to fewer complications, such as infections, seizures, or the need for further surgery, compared to the standard timing of more than 3 months after DHC.
To be eligible for this study, participants need to be adults aged 18 or older who have had a significant brain injury or stroke that required DHC. They also need to be medically stable for surgery and have a specific type of skull shape that is suitable for cranioplasty after 4 weeks. Participants will be monitored for any complications and their recovery outcomes to help determine the best timing for this important surgery. This trial is currently active but not recruiting new participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults of age greater than or equal to 18 years at the time of acute traumatic injury or source of increased intracranial pressure secondary to stroke or intracranial hemorrhage necessitating decompressive hemicraniectomy (DHC)
- • Patient's cranial flap fulfills Craniectomy Contour Class A or B after 4 weeks postoperatively (doi:10.1227/ons.0000000000000689)
- • Medically optimized for general anesthesia/surgery
- Exclusion Criteria:
- • Active systemic infection in weeks 6-8 post-DHC leading up to cranioplasty (e.g. pneumonia, urinary tract infection, soft tissue infection, bacteremia)
- • Cranial infection in the post-DHC period
- • Patient deemed not appropriate for early cranioplasty by attending neurosurgeon
- • Patient mortality prior to 8 weeks post-injury ("injury" defined as "acute traumatic injury or source of increased intracranial pressure causing brain injury secondary to stroke or intracranial hemorrhage")
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported